Cargando…

Early veno-venous haemodiafiltration for sepsis-related multiple organ failure

INTRODUCTION: We conducted a prospective observational study from January 1995 to December 2004 to evaluate the impact on recovery of a major advance in renal replacement therapy, namely continuous veno-venous haemodiafiltration (CVVHDF), in patients with refractory septic shock. METHOD: CVVHDF was...

Descripción completa

Detalles Bibliográficos
Autores principales: Page, Bernard, Vieillard-Baron, Antoine, Chergui, Karim, Peyrouset, Olivier, Rabiller, Anne, Beauchet, Alain, Aegerter, Philippe, Jardin, François
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1414012/
https://www.ncbi.nlm.nih.gov/pubmed/16356224
http://dx.doi.org/10.1186/cc3886
_version_ 1782127104004980736
author Page, Bernard
Vieillard-Baron, Antoine
Chergui, Karim
Peyrouset, Olivier
Rabiller, Anne
Beauchet, Alain
Aegerter, Philippe
Jardin, François
author_facet Page, Bernard
Vieillard-Baron, Antoine
Chergui, Karim
Peyrouset, Olivier
Rabiller, Anne
Beauchet, Alain
Aegerter, Philippe
Jardin, François
author_sort Page, Bernard
collection PubMed
description INTRODUCTION: We conducted a prospective observational study from January 1995 to December 2004 to evaluate the impact on recovery of a major advance in renal replacement therapy, namely continuous veno-venous haemodiafiltration (CVVHDF), in patients with refractory septic shock. METHOD: CVVHDF was implemented after 6–12 hours of maximal haemodynamic support, and base excess monitoring was used to evaluate the improvement achieved. Of the 60 patients studied, 40 had improved metabolic acidosis after 12 hours of CVVHDF, with a progressive improvement in all failing organs; the final mortality rate in this subgroup was 30%. In contrast, metabolic acidosis did not improve in the remaining 20 patients after 12 hours of CVVHDF, and the mortality rate in this subgroup was 100%. The crude mortality rate for the whole group was 53%, which is significantly lower than the predicted mortality using Simplified Acute Physiology Score II (79%). CONCLUSION: Early CVVHDF may improve the prognosis of sepsis-related multiple organ failure. Failure to correct metabolic acidosis rapidly during the procedure was a strong predictor of mortality.
format Text
id pubmed-1414012
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14140122006-03-28 Early veno-venous haemodiafiltration for sepsis-related multiple organ failure Page, Bernard Vieillard-Baron, Antoine Chergui, Karim Peyrouset, Olivier Rabiller, Anne Beauchet, Alain Aegerter, Philippe Jardin, François Crit Care Research INTRODUCTION: We conducted a prospective observational study from January 1995 to December 2004 to evaluate the impact on recovery of a major advance in renal replacement therapy, namely continuous veno-venous haemodiafiltration (CVVHDF), in patients with refractory septic shock. METHOD: CVVHDF was implemented after 6–12 hours of maximal haemodynamic support, and base excess monitoring was used to evaluate the improvement achieved. Of the 60 patients studied, 40 had improved metabolic acidosis after 12 hours of CVVHDF, with a progressive improvement in all failing organs; the final mortality rate in this subgroup was 30%. In contrast, metabolic acidosis did not improve in the remaining 20 patients after 12 hours of CVVHDF, and the mortality rate in this subgroup was 100%. The crude mortality rate for the whole group was 53%, which is significantly lower than the predicted mortality using Simplified Acute Physiology Score II (79%). CONCLUSION: Early CVVHDF may improve the prognosis of sepsis-related multiple organ failure. Failure to correct metabolic acidosis rapidly during the procedure was a strong predictor of mortality. BioMed Central 2005 2005-11-09 /pmc/articles/PMC1414012/ /pubmed/16356224 http://dx.doi.org/10.1186/cc3886 Text en Copyright © 2005 Page et al.; licensee BioMed Central Ltd.
spellingShingle Research
Page, Bernard
Vieillard-Baron, Antoine
Chergui, Karim
Peyrouset, Olivier
Rabiller, Anne
Beauchet, Alain
Aegerter, Philippe
Jardin, François
Early veno-venous haemodiafiltration for sepsis-related multiple organ failure
title Early veno-venous haemodiafiltration for sepsis-related multiple organ failure
title_full Early veno-venous haemodiafiltration for sepsis-related multiple organ failure
title_fullStr Early veno-venous haemodiafiltration for sepsis-related multiple organ failure
title_full_unstemmed Early veno-venous haemodiafiltration for sepsis-related multiple organ failure
title_short Early veno-venous haemodiafiltration for sepsis-related multiple organ failure
title_sort early veno-venous haemodiafiltration for sepsis-related multiple organ failure
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1414012/
https://www.ncbi.nlm.nih.gov/pubmed/16356224
http://dx.doi.org/10.1186/cc3886
work_keys_str_mv AT pagebernard earlyvenovenoushaemodiafiltrationforsepsisrelatedmultipleorganfailure
AT vieillardbaronantoine earlyvenovenoushaemodiafiltrationforsepsisrelatedmultipleorganfailure
AT cherguikarim earlyvenovenoushaemodiafiltrationforsepsisrelatedmultipleorganfailure
AT peyrousetolivier earlyvenovenoushaemodiafiltrationforsepsisrelatedmultipleorganfailure
AT rabilleranne earlyvenovenoushaemodiafiltrationforsepsisrelatedmultipleorganfailure
AT beauchetalain earlyvenovenoushaemodiafiltrationforsepsisrelatedmultipleorganfailure
AT aegerterphilippe earlyvenovenoushaemodiafiltrationforsepsisrelatedmultipleorganfailure
AT jardinfrancois earlyvenovenoushaemodiafiltrationforsepsisrelatedmultipleorganfailure